SLC5A2 and type 2 diabetes mellitus: Similar results were obtained for non-obese participants with T2DM (GLP-1 RAs vs. placebo: RR 0.86 [0.76–0.98]; SGLT-2 inhibitors vs. placebo: RR 0.90 [0.79–1.02]; GLP-1 RAs vs. SGLT-2 inhibitors: RR 0.93 [0.75–1.16]), but there was significant heterogeneity among the studies (I2 = 49%, P = 0.040).